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Engaging the private sector to strengthen NCD prevention 
and control
All around the world private enterprises inﬂ uence health 
through the sale of both harmful and health-promoting 
commodities, as well as lobbying and marketing 
activities.1 As globalisation further strengthens the 
role of the private sector as a major driver of the non-
communicable disease (NCD) pandemic, engaging 
with the private sector to prevent and control these 
conditions has become increasingly important. In 
recognition of this fact, the 2011 UN High-Level Political 
Declaration on NCDs2 called on the private sector to take 
action in areas such as promoting healthy workplaces, 
improving aﬀ ordability and access to medicines, and 
reformulating unhealthy food products. In 2014, 
Ministers at the UN General Assembly noted that limited 
progress had been made in these areas.3 The 67th World 
Health Assembly established a working group (under 
the auspices of the Global Coordination Mechanism on 
NCDs4) to develop more granular recommendations for 
governments. This Comment provides an overview of 
these recommendations, which are described in detail in 
its full report.5
The working group noted several impediments to 
progress, including a lack of awareness around the 
potential role of the private sector, a lack of supporting 
regulation and legislative capacity, conﬂ icting public and 
private objectives, constrained government capability to 
engage with the wide range of private sector entities, 
and inadequate use of data to support action, target 
setting, and monitoring processes.
The group noted that conﬂ icts of interest are not 
ubiquitous and many commercial entities have 
objectives that closely align with NCD prevention 
and control. The private sector is heterogeneous, and 
many businesses inﬂ uence NCDs positively, including 
those involved with pharmaceuticals, food, sports and 
ﬁ tness, insurance, banking, advertising, entertainment, 
transport, and infrastructure. Engagement with 
businesses can mitigate harm and leverage expertise 
and resources to bolster the global NCD response. 
This pro-engagement perspective resonates with 
calls in the Addis Abba Action Agenda to “unlock the 
transformative power of the private sector”;6 however, 
counterpoised paragraphs acknowledge the need for 
strengthened regulatory frameworks to align business 
incentives with public goals. Balancing potential gains 
to public health with potential conﬂ icts of interest 
is an ongoing challenge, and the working group has 
developed a series of principles to facilitate eﬀ ective 
public–private engagement.
First, there must be clear policy goals for the issue 
at hand, whether these are expanding access to 
medications, improving public transport, regulating 
harmful substances, or upgrading water and sanitation 
infrastructure. Clear goals require careful problem 
deﬁ nition, articulation of the desired outcome, and a 
system-wide approach for evaluating potential solutions.
Second, all of the stakeholders that might have 
a role to play in a potential partnership to prevent 
and manage NCDs should be identiﬁ ed, including 
academics, government departments, civil society, 
philanthropic organisations, and the full gamut of 
private sector entities. Full assessments of the potential 
costs, beneﬁ ts, risks, and impacts are required before 
public health agencies enter into speciﬁ c partnerships.
Due diligence is essential and should pay special 
attention to the scope and purpose of the mooted 
relationship, the partner’s interests, policies, values, and 
past performance. It is important to actively manage 
real, perceived, and potential conﬂ icts of interest, and 
to maintain transparent interactions at all times. Such 
transparency might include making correspondences 
and meeting minutes publicly available. The need to 
identify and manage conﬂ icts of interest should be 
communicated throughout all relevant institutions, with 
high-level organisational oversight. There should be clear 
rules on disclosing and managing conﬂ icts for individual 
oﬃ  cials, especially around gifts, providing services, and 
managing research funding. Failure to manage perceived 
conﬂ icts of interest can cause reputational damage, 
undermine public health work in other areas, and 
whitewash the image of unscrupulous companies.
The parties involved in any partnership should consider 
whether formal arrangements such as legal contracts 
or memoranda of understanding are required for the 
proposed work. Ongoing monitoring and evaluation is 
important to ensure that both parties play by the rules. 
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Public–private enterprises are more likely to succeed 
where governments have established statutory and 
regulatory frameworks that support partnerships 
and protect the public. Governments can also help to 
align private sector incentives with national objectives 
through the use of taxes, subsidies, and reduced 
compliance costs. 
Several of these recommendations are mirrored in 
the recently adopted WHO Framework for Engagement 
with Non-State Actors.7 Although this framework 
deals exclusively with WHO partnerships, the themes 
of due diligence, risk assessment, transparency, and 
accountability all feature prominently. Both sets of 
recommendations are based on the assumption that 
some degree of engagement with many private sector 
actors is essential for progress in contemporary global 
health.
Critics of private sector engagement argue that 
any such collaboration exposes population health to 
undue commercial inﬂ uence and can lead to the so-
called corporate capture of public health institutions.8 
Although there are acknowledged risks, it is important 
to recognise the diversity among private-sector actors 
and the absolute centrality of commercial determinants 
of health in the 21st century.1 Although the public health 
community can feel justiﬁ ably uneasy about working 
with private sector actors directly causing disease and 
disability, the general consensus is that some degree of 
engagement is essential (with the exception of arms 
and tobacco).9 The working group’s ﬁ ndings chart a 
course though this diﬃ  cult territory. 
The principles outlined here and detailed in the 
full report5 represent one step in an iterative process 
that will be strengthened by ongoing discussion. 
Discriminating between conﬂ icts and conﬂ uences of 
interest is complex and guidance will need to evolve 
over time. The Global Coordination Mechanism is an 
organisational partnership that already brings public, 
private, and third sector agents together in pursuit 
of NCD prevention and control. In its role as a broker 
and convener we welcome ongoing dialogue and 
engagement on this issue.
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